West Pharmaceutical Services Inc. ($WST) Stock Forecast: Up 5.2% Today

What is West Pharmaceutical Services Inc.?

West Pharmaceutical Services, Inc. (WST) specializes in manufacturing high-value product components for the healthcare industry, particularly in diabetes and obesity treatments. The company recently reported strong financial results for Q4 2025 and provided optimistic guidance for 2026, citing growth in GLP-1 demand and strategic investments in innovation.

Why is West Pharmaceutical Services Inc. going up?

WST stock is up 5.2% on Feb 13, 2026 16:11

• The bullish movement in WST stock today can be attributed to the company's robust Q4 2025 results and optimistic 2026 guidance, which exceeded market expectations and showcased strong revenue growth driven by high-value product components, GLP-1 demand, and biologics recovery.
• Despite concerns raised in previous quarters about slipping net profit margins and trailing revenue growth, the company's forecasted profit for 2026 above estimates, fueled by strong demand for drug components, has instilled confidence in investors and contributed to the stock's positive performance.
• The tension between bullish growth narratives and financial challenges seems to have been alleviated by the company's updated outlook, emphasizing organic net sales growth and highlighting the positive impact of underlying demand and product mix on its future financial prospects.
• Overall, WST's stock surge today reflects investor optimism surrounding the company's ability to capitalize on the expanding GLP-1 market, strategic investments in innovation, and the promising outlook for its high-value product components in the healthcare industry.

WST Price Chart

WST Technical Analysis

WST News

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2025 Earnings Call Transcript

West Pharmaceutical Services, Inc. reported solid Q4 2025 results, with revenues exceeding expectations and strong growth in high-value product components, driven by GLP-1 demand, Annex 1 upgrades, and biologics recovery. The company provided optimistic 2026 guidance, anticipating 5% to 7% organic revenue growth and double-digit EPS growth, while conservatively estimating GLP-1 growth. They also highlighted strategic investments in capacity, innovation with products like West Synchrony, and the long-term opportunities presented by biologics, Annex 1 regulations, and the expanding GLP-1 market.

https://www.insidermonkey.com/blog/west-pharmaceutical-services-inc-nysewst-q4-2025-earnings-call-transcript-1695394/

West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives

West Pharmaceutical Services (WST) reported Q3 FY 2025 results with revenue of US$804.6 million and basic EPS of US$1.94, however, its net profit margin slipped to 16.3% from 17.4% a year earlier. This margin contraction and a 6% revenue growth, which trails the broader US market, are raising concerns, especially given the company's high P/E ratio of 35.6x compared to a DCF fair value of US$54.99, indicating that optimistic growth expectations are already priced in.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/west-pharmaceutical-services-margins-slip-to-163-raising-que/amp

West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives

West Pharmaceutical Services (WST) reported its FY 2025 third-quarter results, showing a slip in net profit margins from 17.4% to 16.3% and 6% revenue growth, which trails the broader US market. Despite analyst consensus forecasting margin improvement and future revenue potential driven by GLP-1 and high-value product components, the company's P/E ratio of 35.6x is significantly higher than peers and its DCF fair value, raising concerns for cautious investors. The article highlights a tension between bullish growth narratives and current financial performance, noting that current figures challenge some market expectations.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/west-pharmaceutical-services-margins-slip-to-163-raising-que

West Pharma forecasts 2026 profit above estimates on strong demand for drug components

West Pharmaceutical has forecasted its annual profit for 2026 to be above Wall Street estimates, driven by a strong demand for its medical components used in diabetes and obesity treatments, particularly GLP-1 related drugs. Despite concerns about the growth of oral weight-loss medications, CEO Eric Green anticipates continued growth for both injectable and oral formats, including an incremental boost from upcoming generic GLP-1 launches in several countries. The company also surpassed its fourth-quarter expectations due to robust demand for its proprietary products.

https://whtc.com/2026/02/12/west-pharma-forecasts-2026-profit-above-estimates-on-strong-demand-for-drug-components/

West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook

West Pharmaceutical Services (WST) reported a 5.2% stock increase following strong 2025 results, with sales reaching US$3.07 billion and net income at US$493.7 million. The company issued encouraging 2026 guidance, expecting first-quarter net sales of US$770-$790 million and full-year sales of US$3.22-$3.28 billion, emphasizing organic net sales growth as a key driver. This updated outlook helps investors understand the impact of underlying demand and product mix on the company's financial performance.

https://finance.yahoo.com/news/west-pharmaceutical-services-wst-5-002255335.html

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 6.6% Today

Solana ($SOL) Crypto Forecast: Up 7.9% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 5.8% Today

Sonos Inc. ($SONO) Stock Forecast: Down 5.2% Today

Franco-Nevada Corp. ($FNV) Stock Forecast: Up 5.1% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Up 7.6% Today

Rocket Companies Inc ($RKT) Stock Forecast: Up 5.1% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Up 5.4% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 6.5% Today

West Pharmaceutical Services Inc. Price History

13.01.2026 - WST Stock was up 5.2%

• The bullish movement in WST stock today can be attributed to the company's robust Q4 2025 results and optimistic 2026 guidance, which exceeded market expectations and showcased strong revenue growth driven by high-value product components, GLP-1 demand, and biologics recovery.
• Despite concerns raised in previous quarters about slipping net profit margins and trailing revenue growth, the company's forecasted profit for 2026 above estimates, fueled by strong demand for drug components, has instilled confidence in investors and contributed to the stock's positive performance.
• The tension between bullish growth narratives and financial challenges seems to have been alleviated by the company's updated outlook, emphasizing organic net sales growth and highlighting the positive impact of underlying demand and product mix on its future financial prospects.
• Overall, WST's stock surge today reflects investor optimism surrounding the company's ability to capitalize on the expanding GLP-1 market, strategic investments in innovation, and the promising outlook for its high-value product components in the healthcare industry.

04.01.2026 - WST Stock was up 5.0%

• West Pharmaceutical Services (WST) witnessed a strong bullish movement in the market today, with the following factors contributing to this positive trend:
• Analysts maintaining a "Buy" consensus rating for WST, setting an average target price of $335.78, reflecting confidence in the company's future performance.
• Truist Financial Corp significantly increased its stake in WST by 73.7% in the third quarter, indicating strong institutional investor confidence in the company's growth prospects.
• Despite a slight decrease in the average one-year price target for WST, the new target still represents a notable 23.61% increase from the latest closing price, showcasing optimism about the company's potential.
• The recent launch of DuPont's new Liveo C6-8XX Liquid Silicone Rubber series for healthcare applications might have indirectly influenced investor sentiment towards WST, highlighting the continuous innovation and advancements in the healthcare sector where WST operates.

06.00.2026 - WST Stock was up 5.7%

• Despite executive insider selling and recent performance challenges, West Pharmaceutical Services Inc. exceeded expectations with its Q3 earnings and revenue. This likely contributed to the positive movement in the company's stock.
• The growing investments from North Growth Management Ltd. and Ethic Inc. in WST suggest increasing confidence in the company's future, especially with the optimistic FY2025 guidance provided.
• Thermo Fisher Scientific Inc. ($TMO) recently announced a quarterly dividend and a stock buyback program, potentially boosting market sentiment towards healthcare companies, including WST.
• In summary, West Pharmaceutical Services Inc.'s bullish stock movement today could be attributed to its strong financial performance, increased stake acquisitions, and positive developments in the healthcare sector.

21.10.2025 - WST Stock was up 5.1%

• The decrease in short interest indicates a positive sentiment among investors towards WST.
• The reduction in shares sold short could suggest that investors are becoming more confident in the company's future prospects.
• This decrease in short interest may have contributed to increased buying pressure on WST, leading to its bullish movement today.

12.01.2026 - WST Stock was down 7.5%

• Today, despite reporting strong Q4 2025 earnings and issuing optimistic guidance for FY 2026, West Pharmaceutical Services (WST) saw a bearish movement in its stock. Possible reasons for this unexpected market reaction include:
• The market potentially factoring in the positive earnings beat and revenue results from Q4 2025, leading to profit-taking.
• Analysts expressing concerns about the high valuation of WST stock, with implications raised by TipRanks' AI Analyst, Spark.
• A slight decrease in operating margin, even though the free cash flow margin improved, raising questions about future profitability and efficiency.
• General market conditions or sector-specific factors that overshadowed West Pharmaceutical Services' positive financial performance.

12.01.2026 - WST Stock was down 3.4%

• Despite posting solid Q4 and 2025 results with strong revenue growth and beating earnings estimates, West Pharmaceutical Services (WST) experienced a bearish movement in the stock market.
• The bearish trend could be linked to an AI Analyst assigning a Neutral rating to WST, citing high valuation concerns despite the company's strong financial performance.
• Moreover, investors seemed worried about the planned divestiture of its SmartDose 3.5mL system, raising uncertainties about future revenue streams and prompting a sell-off.
• In conclusion, while the company showcased robust financial performance and positive 2026 outlook, market sentiment and valuation worries likely played a part in the stock's bearish movement.

06.01.2026 - WST Stock was up 5.2%

• Strong bullish movement in the market today for WST.
• Announcement of an integrated syringe system to streamline pharmaceutical development and supply chain management, with positive industry feedback.
• Expectations of earnings growth and higher revenues for the quarter ended December 2025, despite some analysts expressing dissenting views.
• Anticipation of insights into demand trends for injectable therapies and growth projections in the upcoming earnings reveal.
• WST's commitment to driving innovation in cancer treatment packaging, reflecting dedication to advancing healthcare solutions and making an impact in the fight against cancer.

16.00.2026 - WST Stock was down 4.2%

• Institutional investor Conning Inc. decreased its stake in AbbVie Inc., suggesting a potential shift in focus away from traditional pharmaceutical companies like AbbVie. This shift could impact related stocks such as WST.
• Analysts indicate that WST may be overvalued at its current price. Concerns about revenue headwinds and project conversion risks likely contributed to the stock's bearish movement.
• Despite positive growth prospects in the GLP-1 market and regulatory upgrades, challenges including revenue headwinds and profitability risks may have overshadowed the positive outlook, leading to the bearish market movement.
• The combination of reduced institutional investment in AbbVie, concerns about WST's overvaluation and revenue challenges, and potential risks in project conversions likely influenced the bearish movement in WST's stock today.

23.00.2026 - WST Stock was down 6.9%

• Despite positive developments like the sale of SmartDose rights to AbbVie and a "strong-buy" rating from Zacks Research, WST saw a decline in its market value today.
• The market's negative reaction may be attributed to concerns about the impact of selling a product that contributed significantly to WST's revenue in 2025, leading to uncertainties regarding future earnings.
• While the industry outlook is favorable and growth prospects are promising, investors may be wary of WST's strategic shift and the challenges highlighted in recent reports.
• The extended collaboration between BD and Ypsomed to target the expanding biologics market could intensify competition in the drug delivery systems sector, creating additional pressure on WST's market standing.

23.09.2025 - WST Stock was up 14.5%

• The bullish movement in WST could be attributed to the anticipation of strong Q3 earnings driven by robust demand for GLP-1 and biologics products.
• Investors seem optimistic about WST's ability to navigate challenges such as labor constraints, tariffs, and plant shutdowns, which might have positively impacted the stock price.
• The market may be pricing in the potential for WST to outperform expectations despite margin pressures, showcasing confidence in the company's resilience and growth prospects.

23.09.2025 - WST Stock was up 10.7%

• WST stock experienced a bullish movement today due to the company's strong Q3 earnings beat and raised EPS outlook, driven by robust demand and favorable foreign exchange rates.
• The market responded positively to the company's solid growth in Proprietary Products, reflecting investors' confidence in West Pharmaceutical's ability to capitalize on market opportunities.
• Despite potential challenges such as labor constraints, tariffs, and plant shutdowns, the momentum in GLP-1 and biologics demand seems to have outweighed any margin pressure concerns, further boosting investor sentiment towards WST stock.

06.10.2025 - WST Stock was down 4.0%

• Analysts are bullish on WST, predicting a potential surge of 25.41% in the stock price.
• Despite positive analyst sentiment, the market may have reacted to other factors causing a bearish movement in WST.
• It is possible that external market conditions or unforeseen events impacted WST negatively, leading to the bearish trend observed today.